THERAPY DOSSIER · th-fa22dbc2cc96

Euphorbia characias subsp. wulfenii methanol extract of aerial parts and its isolated quercetin glycosides (quercitrin, hyperoside, guaijaverin)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29920357 ↗2018Reported benefit

In vivo wound-healing activity of Euphorbia characias subsp. wulfenii: Isolation and quantification of quercetin glycosides as bioactive compounds.

MixedWoundSprague-Dawley rats (mouse strain not stated)MaleTopical application to wounds (ointment); systemic route for anti-inflammatory assay not specified

Model: Linear incision and circular excision skin wound models, with acetic acid-induced increase in capillary permeability as an acute inflammation model

The methanol extract of the aerial parts showed significant wound healing activity (43.04% in the linear incision model, 65.24% in the circular excision model) and 34.74% anti-inflammatory activity. Bioassay-guided fractionation identified quercitrin, hyperoside and guaijaverin as the active consti…

Extraction: extract · Supplied extraction confidence: 0.66. Machine-extracted fields require source verification.

Loading the evidence…